Latest Healthcare News

McPherson’s Limited reported a 3.9% revenue decline in FY25 due to shedding non-strategic brands, while its core health and beauty brands grew modestly. The company’s transition to a wholesaler and third-party logistics model marks a pivotal shift aimed at long-term growth despite a widened net loss.

Apiam Animal Health reported modest revenue growth but a sharp net profit decline in FY25, launching a Strategic Reset program under new leadership. The company also received a $0.88 per share acquisition proposal from Adamantem Capital Management.

Sigma Healthcare reports a robust FY25 performance post-merger with Chemist Warehouse Group, delivering strong revenue growth and upgraded synergy targets. The company signals continued expansion and efficiency gains heading into FY26.

Sigma Healthcare reports a robust 41% rise in EBIT following its merger with Chemist Warehouse, upgrading synergy targets and expanding its retail footprint internationally.

Sigma Healthcare has completed a reverse acquisition merger with Chemist Warehouse, reporting $6 billion in revenue and declaring a fully franked dividend. The merger reshapes Australia’s pharmacy landscape with ambitious synergy targets and operational shifts.

Clever Culture Systems has validated and launched an AI-driven analysis module for smaller contact plates, significantly expanding its pharmaceutical market reach and recurring revenue potential.

ParagonCare Limited reported a solid FY25 with $3.6 billion in revenue and $95.2 million underlying EBITDA, marking progress in its integration and growth strategy across Asia Pacific. The company is poised for further profitability improvements and expansion in FY26.

Paragon Care Limited reported solid FY25 results with revenue climbing to $3.61 billion and underlying EBITDA rising 3%, driven by successful integration and expansion into new healthcare segments.

Paragon Care Limited reported a robust 22% increase in revenue to $3.61 billion for FY25, driven by organic growth and key acquisitions including CH2 Holdings and Oborne Health Supplies. The company also refinanced its debt facilities and expanded into the dental market post-year-end.

EBOS Group Limited reported a 7% drop in revenue and a 21% fall in net profit for FY2025, reflecting ongoing cost pressures and restructuring impacts. The company declared a final dividend, signaling cautious optimism despite the earnings setback.

EBOS Group Limited reported solid FY25 results with 12% revenue growth and strategic acquisitions, setting sights on continued expansion and operational efficiency in FY26.

EBOS Group Limited reported a steady FY25 with 12% revenue growth and EBITDA in line with guidance, driven by strong healthcare and animal care segments. The company signals confidence with maintained dividends and a positive FY26 outlook.